PATANASE
LOE ApproachingNDANASALSPRAY, METERED
Approved
Apr 2008
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
4/8 — Partial
PATANASE by Novartis is 1 -receptor antagonist. First approved in 2008.
Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PATANASE is olopatadine, a nasal spray H1-receptor antagonist approved by the FDA in 2008 for allergic rhinitis. It works by blocking histamine receptors to reduce allergic symptoms including nasal congestion, sneezing, and itching. The drug is administered as a metered nasal spray for topical delivery.
$0.04BPart D
LOE ApproachingProduct approaching loss of exclusivity with minimal Medicare Part D penetration (73 claims in 2023) signals a mature, contracted market with limited team expansion opportunities.
Mechanism of Action
1 -receptor antagonist. The antihistaminic activity of olopatadine has been documented in isolated tissues, animal models, and humans.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Safety of PATANASE Nasal Spray in Patients With Perennial Allergic Rhinitis
Started Nov 2008
1,260 enrolled
Perennial Allergic Rhinitis
Safety and Pharmacokinetics of Patanase in Pediatric Patients 2 to < 6 Years of Age
Started Oct 2008
132 enrolled
Allergic Rhinitis
Career Relevance
Zero linked job openings and approaching LOE status indicate PATANASE is in maintenance mode with minimal hiring. Career opportunities are limited to existing brand team roles focused on defending market share against generics and managing decline.
Brand Manager
Worked on PATANASE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.